2024
B cell and aquaporin‐4 antibody relationships with neuromyelitis optica spectrum disorder activity
Bennett J, Pittock S, Paul F, Kim H, Irani S, O'Connor K, Patterson K, Smith M, Gunsior M, Mittereder N, Rees W, Cimbora D, Cree B. B cell and aquaporin‐4 antibody relationships with neuromyelitis optica spectrum disorder activity. Annals Of Clinical And Translational Neurology 2024, 11: 2792-2798. PMID: 39222408, PMCID: PMC11514900, DOI: 10.1002/acn3.52171.Peer-Reviewed Original ResearchNeuromyelitis optica spectrum disorderAquaporin-4B cellsAquaporin-4 immunoglobulin GCirculating B cell subsetsAQP4-IgG titerN-MOmentum studyB-cell countsB cell subsetsBaseline to timePost hoc analysisInebilizumab treatmentAQP4-IgGCD20<sup>+</sup>Subset countsGene signatureHoc analysisInebilizumabNo differenceImmunoglobulin GNeuromyelitisBaselineDisordered activityTitersSpectrum disorderA Noncanonical CD56dimCD16dim/- NK Cell Subset Indicative of Prior Cytotoxic Activity Is Elevated in Patients with Autoantibody-Mediated Neurologic Diseases.
Yandamuri S, Filipek B, Lele N, Cohen I, Bennett J, Nowak R, Sotirchos E, Longbrake E, Mace E, O'Connor K. A Noncanonical CD56dimCD16dim/- NK Cell Subset Indicative of Prior Cytotoxic Activity Is Elevated in Patients with Autoantibody-Mediated Neurologic Diseases. The Journal Of Immunology 2024, 212: 785-800. PMID: 38251887, PMCID: PMC10932911, DOI: 10.4049/jimmunol.2300015.Peer-Reviewed Original ResearchConceptsNeuromyelitis optica spectrum disorderAb-dependent cellular cytotoxicityNK cellsMyasthenia gravisMG patientsInduced Ab-dependent cellular cytotoxicityNK cell-mediated effector functionsPeripheral blood immune cell populationsCell-mediated effector functionsNeuromyelitis optica spectrum disorder patientsBlood immune cell populationsAb-dependent cellular cytotoxicity activityNK marker CD56NK cell markersHLA-DR expressionNK cell subsetsExpression of perforinImmune cell populationsAutoimmune myasthenia gravisElevated disease burdenHLA-DRCell subsetsCellular cytotoxicityChemokine receptorsMultiparameter immunophenotyping
2019
Early B cell tolerance defects in neuromyelitis optica favour anti-AQP4 autoantibody production
Cotzomi E, Stathopoulos P, Lee CS, Ritchie AM, Soltys JN, Delmotte FR, Oe T, Sng J, Jiang R, K A, Vander Heiden JA, Kleinstein SH, Levy M, Bennett JL, Meffre E, O’Connor K. Early B cell tolerance defects in neuromyelitis optica favour anti-AQP4 autoantibody production. Brain 2019, 142: 1598-1615. PMID: 31056665, PMCID: PMC6536857, DOI: 10.1093/brain/awz106.Peer-Reviewed Original ResearchConceptsNeuromyelitis optica spectrum disorderB cell tolerance checkpointsNMOSD patientsNaïve B cellsAQP4 autoantibodiesTolerance checkpointsHealthy donorsB cellsEarly B cell tolerance checkpointsPeripheral B cell tolerance checkpointsMature naïve B cellsB cell tolerance defectsSeropositive NMOSD patientsOptica spectrum disorderRare autoimmune disorderNaïve B-cell compartmentB cell compartmentB cell populationsAquaporin-4 water channelsPathogenic autoantibodiesAutoantibody productionOptic nerveAutoimmune disordersSevere inflammationSpinal cordAutoantibodies against Neurologic Antigens in Nonneurologic Autoimmunity
Stathopoulos P, Chastre A, Waters P, Irani S, Fichtner ML, Benotti ES, Guthridge JM, Seifert J, Nowak RJ, Buckner JH, Holers VM, James JA, Hafler DA, O’Connor K. Autoantibodies against Neurologic Antigens in Nonneurologic Autoimmunity. The Journal Of Immunology 2019, 202: ji1801295. PMID: 30824481, PMCID: PMC6452031, DOI: 10.4049/jimmunol.1801295.Peer-Reviewed Original ResearchConceptsSystemic lupus erythematosusRheumatoid arthritisControl cohortNeuromyelitis optica spectrum disorderSurface AgOptica spectrum disorderMyelin oligodendrocyte glycoproteinHealthy donor seraType 1 diabetesB cell toleranceNeurologic autoimmunitySLE patientsLupus erythematosusSuch autoantibodiesT1D patientsAutoimmune diseasesHigh titer AbsOligodendrocyte glycoproteinSystemic autoimmunityDonor seraLarge cohortRare caseAutoantibodiesAquaporin-4Cell tolerance
2016
Restoring immune tolerance in neuromyelitis optica
Bar-Or A, Steinman L, Behne J, Benitez-Ribas D, Chin P, Clare-Salzler M, Healey D, Kim J, Kranz D, Lutterotti A, Martin R, Schippling S, Villoslada P, Wei C, Weiner H, Zamvil S, Smith T, Yeaman M, Aktas O, Amezcua L, Appiwatanakul M, Asgari N, Banwell B, Bennett J, Bowen J, Cabre P, Chitnis T, Cohen J, De Seze J, Fujihara K, Han M, Hellwig K, Hintzen R, Hooper D, Iorio R, Jacob A, Jarius S, Kim H, Kissani N, Klawiter E, Kleiter I, Lana-Peixoto M, Leite M, Levy M, Lublin F, Draayer Y, Marignier R, Matiello M, Nakashima I, O’Connor K, Palace J, Pandit L, Paul F, Prayoonwiwat N, Riley C, Ruprecht K, Saiz A, Siritho S, Tenembaum S, Weinshenker B, Wingerchuk D, Würfel J. Restoring immune tolerance in neuromyelitis optica. Neurology Neuroimmunology & Neuroinflammation 2016, 3: &na;. PMID: 27648464, PMCID: PMC5015540, DOI: 10.1212/nxi.0000000000000277.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsNMO/SDImmune toleranceAquaporin-4Neuromyelitis optica spectrum disorderNormal host defense mechanismsOptica spectrum disorderHost defense mechanismsOral tolerizationNeuromyelitis opticaOptic nerveParticular brain regionsAutoimmune diseasesAstrocyte functionSpinal cordClinical variantsNovel therapiesDominant autoantigenClinical developmentPotential cureB cellsBrain regionsExperimental modelDiseaseCharacteristic phenotypeAutoantigens